Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10.8% – Here’s Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was up 10.8% during mid-day trading on Thursday . The company traded as high as $4.98 and last traded at $5.1060. Approximately 10,575,171 shares were traded during trading, a decline of 47% from the average daily volume of 19,982,045 shares. The stock had previously closed at $4.61.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on RXRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. Finally, Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $9.40.

Recursion Pharmaceuticals Price Performance

The firm has a market cap of $2.46 billion, a P/E ratio of -2.63 and a beta of 0.95. The business’s fifty day simple moving average is $4.46 and its 200-day simple moving average is $5.03. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The firm had revenue of $5.18 million during the quarter, compared to analyst estimates of $19.36 million. During the same period last year, the company earned ($0.34) earnings per share. The business’s revenue for the quarter was down 80.1% on a year-over-year basis. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 124,403 shares of the stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the sale, the insider directly owned 611,135 shares of the company’s stock, valued at approximately $2,695,105.35. This represents a 16.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Blake Borgeson sold 220,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $4.36, for a total transaction of $959,200.00. Following the sale, the director directly owned 6,649,863 shares in the company, valued at $28,993,402.68. This trade represents a 3.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 585,786 shares of company stock valued at $2,558,598 in the last quarter. 8.43% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Recursion Pharmaceuticals by 10.3% during the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock worth $194,127,000 after acquiring an additional 3,708,975 shares in the last quarter. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $16,040,000. Bank Pictet & Cie Europe AG bought a new position in shares of Recursion Pharmaceuticals during the 3rd quarter valued at $7,954,000. Geode Capital Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 20.7% during the 2nd quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after purchasing an additional 1,332,428 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in Recursion Pharmaceuticals by 109.9% in the 3rd quarter. Two Sigma Investments LP now owns 2,450,805 shares of the company’s stock worth $11,960,000 after purchasing an additional 1,282,992 shares during the period. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.